ASH 2023 | Novel BTKi strategies in indolent B-cell malignancies: pirtobrutinib for FL and MZL
Catherine Coombs, MD, UC Irvine Health, Orange, CA, briefly discusses novel BTK inhibitor (BTKi) strategies in indolent B-cell malignancies, focusing on the covalent BTKi pirtobrutinib which was investigated in the Phase I/II BRUIN trial (NCT03740529). Pirtobrutinib has been shown to be efficacious in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), as well as exhibiting an overall response rate (ORR) of around 50% in follicular lymphoma (FL) and marginal zone lymphoma (MZL). At present, no BTKi’s are approved for use in FL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Janssen, TG Therapeutics, Loxo Oncology/Eli Lilly and Company, AstraZeneca, Genentech, AbbVie, Mingsight, BeiGene, MEI Pharma
Consultancy: Octapharma, Loxo Oncology/Eli Lilly and Company, AstraZeneca, Genentech, AbbVie, BeiGene
Current equity holder in publicly-traded company: Bluebird Bio
Research Funding: Loxo Oncology/Eli Lilly and Company, AbbVie
Board of Directors/Advisory committee: AstraZeneca, Genentech, AbbVie, BeiGene
